Newron Pharmaceuticals S.p.A. (SWX: NWRN)

Newron Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 4, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	162	287	226	204	291	215
Market Cap Growth	26.85%	26.85%	10.73%	-29.80%	35.75%	-8.41%
Enterprise Value	195	341	328	263	356	240
Last Close Price	8.48	0.49	0.51	0.61	1.12	1.40
PE Ratio	-	-3.77	-2.10	-2.32	-2.67	-2.28
PS Ratio	17.95	16.70	12.60	10.80	13.46	13.42
PB Ratio	-5.25	-5.25	-4.19	-7.87	-13.54	-16.86
P/FCF Ratio	-5.13	-5.13	-4.65	-3.68	-5.69	-4.01
P/OCF Ratio	-6.35	-6.35	-4.87	-3.94	-6.42	-4.52
EV/Sales Ratio	23.13	19.81	18.23	13.87	16.44	14.98
EV/EBITDA Ratio	-5.68	-5.68	-5.12	-4.21	-5.41	-3.40
EV/EBIT Ratio	-5.36	-5.36	-4.88	-3.98	-5.13	-3.23
EV/FCF Ratio	-20.63	-6.08	-6.73	-4.73	-6.94	-4.48
Debt / Equity Ratio	-1.69	-1.69	-1.74	-2.81	-2.19	-3.40
Debt / FCF Ratio	-1.65	-1.65	-1.93	-1.32	-0.92	-0.81
Asset Turnover	0.17	0.17	0.20	0.23	0.30	0.20
Inventory Turnover	0.77	0.77	1.17	1.06	2.12	1.60
Quick Ratio	0.18	0.18	0.15	0.16	0.17	0.25
Current Ratio	0.60	0.60	0.43	0.54	0.43	0.79
Return on Equity (ROE)	-	-	-	-	-	-2960.65%
Return on Assets (ROA)	-40.36%	-40.36%	-46.51%	-50.63%	-59.24%	-57.78%
Return on Capital (ROIC)	-102.29%	-102.29%	-96.55%	-113.32%	-154.27%	-102.53%
Earnings Yield	-9.98%	-23.51%	-37.79%	-39.11%	-26.86%	-38.85%
FCF Yield	-5.85%	-19.51%	-21.52%	-27.15%	-17.58%	-24.91%
Buyback Yield / Dilution	-48.58%	-48.58%	-16.05%	-61.23%	-38.22%	-72.60%
Total Shareholder Return	-48.58%	-48.58%	-16.05%	-61.23%	-38.22%	-72.60%

Source: S&P Capital IQ. Standard template. Financial Sources.